DE60103537D1 - purine derivatives - Google Patents

purine derivatives

Info

Publication number
DE60103537D1
DE60103537D1 DE60103537T DE60103537T DE60103537D1 DE 60103537 D1 DE60103537 D1 DE 60103537D1 DE 60103537 T DE60103537 T DE 60103537T DE 60103537 T DE60103537 T DE 60103537T DE 60103537 D1 DE60103537 D1 DE 60103537D1
Authority
DE
Germany
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60103537T
Other languages
German (de)
Other versions
DE60103537T2 (en
Inventor
Simon John Mantell
Sandra Marina Monaghan
Peter Thomas Stephenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60103537D1 publication Critical patent/DE60103537D1/en
Application granted granted Critical
Publication of DE60103537T2 publication Critical patent/DE60103537T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE60103537T 2000-06-27 2001-06-14 purine derivatives Expired - Fee Related DE60103537T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0015727 2000-06-27
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (en) 2000-06-27 2001-06-14 Purine derivatives

Publications (2)

Publication Number Publication Date
DE60103537D1 true DE60103537D1 (en) 2004-07-01
DE60103537T2 DE60103537T2 (en) 2005-07-07

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103537T Expired - Fee Related DE60103537T2 (en) 2000-06-27 2001-06-14 purine derivatives

Country Status (42)

Country Link
EP (1) EP1296996B1 (en)
JP (1) JP2004501929A (en)
KR (1) KR20030036248A (en)
CN (1) CN1432020A (en)
AP (1) AP1372A (en)
AR (1) AR028759A1 (en)
AT (1) ATE267836T1 (en)
AU (1) AU2001264164A1 (en)
BG (1) BG107171A (en)
BR (1) BR0111912A (en)
CA (1) CA2412564C (en)
CZ (1) CZ20023992A3 (en)
DE (1) DE60103537T2 (en)
DK (1) DK1296996T3 (en)
DO (1) DOP2001000195A (en)
EA (1) EA200201291A1 (en)
EC (1) ECSP024396A (en)
EE (1) EE200200712A (en)
ES (1) ES2220775T3 (en)
GB (1) GB0015727D0 (en)
GT (1) GT200100119A (en)
HR (1) HRP20020995A2 (en)
HU (1) HUP0301389A3 (en)
IL (1) IL152529A0 (en)
IS (1) IS6580A (en)
MA (1) MA26918A1 (en)
MX (1) MXPA03000078A (en)
NO (1) NO20025975L (en)
NZ (1) NZ521867A (en)
OA (1) OA12294A (en)
PA (1) PA8521001A1 (en)
PE (1) PE20020213A1 (en)
PL (1) PL361384A1 (en)
PT (1) PT1296996E (en)
SI (1) SI1296996T1 (en)
SK (1) SK17332002A3 (en)
SV (1) SV2002000507A (en)
TN (1) TNSN01096A1 (en)
TR (1) TR200401622T4 (en)
UY (1) UY26797A1 (en)
WO (1) WO2002000676A1 (en)
ZA (1) ZA200209557B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (en) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis INDOL DERIVATIVES AS BETA-3-ADRENERGE AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES
SE0201980D0 (en) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (en) 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
JP5011112B2 (en) * 2004-09-20 2012-08-29 イノテック ファーマシューティカルズ コーポレイション Pharmaceuticals for the treatment of inflammatory diseases containing purine derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP5006330B2 (en) 2005-10-21 2012-08-22 ノバルティス アーゲー Human antibodies against IL13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2384337T3 (en) * 2006-04-21 2012-07-03 Novartis Ag Purine derivatives for use as adenosine A2A receptor agonists
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
RU2009120389A (en) 2006-10-30 2010-12-10 Новартис АГ (CH) HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
CA2727709C (en) 2008-06-11 2017-11-14 Lasergen, Inc. Nucleotides and nucleosides and methods for their use in dna sequencing
PL2391366T3 (en) 2009-01-29 2013-04-30 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EA026693B1 (en) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Benzoxazole and benzothiazole derivatives as pi3 kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
JP6130391B2 (en) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Enhanced treatment regimen using MTOR inhibitors
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
JP2016512835A (en) 2013-03-15 2016-05-09 インテリカイン， エルエルシー Combinations of kinase inhibitors and their use
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
JP2002500188A (en) * 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション A2a adenosine receptor agonist
BR9914526A (en) * 1998-10-16 2001-07-03 Pfizer Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
ATE267836T1 (en) 2004-06-15
JP2004501929A (en) 2004-01-22
MXPA03000078A (en) 2003-08-19
TR200401622T4 (en) 2004-08-23
UY26797A1 (en) 2002-01-31
PE20020213A1 (en) 2002-03-19
SI1296996T1 (en) 2004-10-31
NZ521867A (en) 2004-04-30
ECSP024396A (en) 2003-02-06
HRP20020995A2 (en) 2005-02-28
DK1296996T3 (en) 2004-08-16
CN1432020A (en) 2003-07-23
EA200201291A1 (en) 2003-04-24
WO2002000676A1 (en) 2002-01-03
HUP0301389A2 (en) 2003-08-28
GT200100119A (en) 2002-01-31
BR0111912A (en) 2003-05-13
EE200200712A (en) 2004-06-15
CZ20023992A3 (en) 2003-12-17
NO20025975D0 (en) 2002-12-12
AP1372A (en) 2005-02-21
PA8521001A1 (en) 2002-04-25
DE60103537T2 (en) 2005-07-07
EP1296996B1 (en) 2004-05-26
PT1296996E (en) 2004-08-31
PL361384A1 (en) 2004-10-04
HUP0301389A3 (en) 2005-02-28
ZA200209557B (en) 2003-12-02
IL152529A0 (en) 2003-05-29
NO20025975L (en) 2002-12-12
EP1296996A1 (en) 2003-04-02
CA2412564C (en) 2007-10-02
SV2002000507A (en) 2002-07-03
ES2220775T3 (en) 2004-12-16
SK17332002A3 (en) 2004-03-02
OA12294A (en) 2003-11-14
CA2412564A1 (en) 2002-01-03
TNSN01096A1 (en) 2005-11-10
AR028759A1 (en) 2003-05-21
AU2001264164A1 (en) 2002-01-08
IS6580A (en) 2002-10-10
KR20030036248A (en) 2003-05-09
MA26918A1 (en) 2004-12-20
DOP2001000195A (en) 2002-05-15
GB0015727D0 (en) 2000-08-16
BG107171A (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DE60119492D1 (en) purine derivatives
DE60103537D1 (en) purine derivatives
ATE431356T1 (en) 2-AMINOCARBONYL-9H PURINE DERIVATIVE
DE60116260D1 (en) ANTIVIRAL AZAINDOL DERIVATIVES
DE60026861D1 (en) PURINE DERIVATIVES
DK1220863T3 (en) purine derivatives
NO20016109D0 (en) purine derivatives
DE60130463D1 (en) PYRIMIDINE DERIVATIVES
ATE298332T1 (en) DECAHYDRO-ISOCHINOLINE DERIVATIVES
DK1280809T3 (en) Antitumorecteinascidin derivatives
AR028282A1 (en) AMINOFENIL PIRIMIDONA DERIVATIVES
DK1322593T3 (en) O-substituted-6-methyl-tramadol derivatives
DK1246791T3 (en) Aminomethyl-phenyl-cyclohexanone derivatives
ATE374776T1 (en) PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES
NO20024393D0 (en) 2-sulphonylphenyl-4-one derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee